In the wake of the increase in Current Liabilities in the third quarter 2026, Quick Ratio fell to 0 a new company low.

Within Major Pharmaceutical Preparations industry 460 other companies have achieved higher Quick Ratio than Regen Biopharma Inc in third quarter 2026. While Quick Ratio total ranking in the third quarter 2026 has deteriorated compared to the prior quarter from 4497 to 4564.

Explain Quick Ratio?
How much Cash & cash equivalents RGBP�s has?
What are RGBP�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

RGBP Quick Ratio	(Jun 30 2026) Q3	(Mar 31 2026) Q2	(Dec 31 2025) Q1	(Sep 30 2025) Q4	(Jun 30 2025) Q3
Y / Y Current Liabilities Change	31.25 %	-4.24 %	3.18 %	-20.88 %	12.85 %
Y / Y Cash & cash equivalent Change	-86.43 %	-98.61 %	277.01 %	277.01 %	-97.15 %
Quick Ratio MRQ	0	0	0.01	0.01	0
RGBP's Total Ranking	# 4564	# 4497	# 2810	# 3891	# 3847
Seq. Current Liabilities Change	40.44 %	1.26 %	0 %	-7.7 %	2.46 %
Seq. Cash & cash equivalent Change	-11.81 %	-99.61 %	0 %	3849.74 %	-90.97 %

Quick Ratio third quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 461
Healthcare Sector	# 938
Overall Market	# 4564

Quick Ratio Statistics
High	Average	Low
16.16	0.84	0
(Mar 31 2014)		(Jun 30 2026)

Financial Statements
Regen Biopharma Inc 's Current Liabilities	$ 8 Millions	Visit RGBP's Balance sheet
Regen Biopharma Inc 's Cash & cash equivalent	$ 0 Millions	Visit RGBP's Balance sheet
Source of RGBP's Sales		Visit RGBP's Sales by Geography

Cumulative Regen Biopharma Inc 's Quick Ratio

RGBP's Quick Ratio for the trailling 12 Months

RGBP Quick Ratio	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months	(Jun 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	1.39 %	-3.64 %	0.38 %	-0.06 %	6.66 %
Y / Y Cash & cash equivalent TTM Growth	140.09 %	19.37 %	-9.33 %	-60.9 %	-84.78 %
Quick Ratio TTM	0.01	0.01	0.01	0	0
Total Ranking TTM	# 4143	# 4153	# 2129	# 3330	# 3128
Seq. Current Liabilities TTM Growth	8.27 %	-1.08 %	0.75 %	-6.03 %	2.9 %
Seq. Cash & cash equivalent TTM Growth	-1.08 %	-11.99 %	46.78 %	87.88 %	-50.82 %

Quick ratio ranking by company, industry and sector >> Back to RGBP Financial Strength Comparisons >> Go to Compare RGBP Quick Ratio to its Competitors

On the trailing twelve months basis In Spite of the jump in Current Liabilities in the Q3 2026 to $7.89 millions, cumulative Quick Ratio remained unchanged at 0.01 below the Regen Biopharma Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 445 other companies have achieved higher Quick Ratio than Regen Biopharma Inc . While Quick Ratio overall ranking has improved so far to 4143, from total ranking during the twelve months ending second quarter 2026 at 4153.

Explain Quick Ratio?
How much Cash & cash equivalents RGBP�s has?
What are RGBP�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 446
Healthcare Sector	# 915
Within the Market	# 4143

trailing twelve months Quick Ratio Statistics
High	Average	Low
1.39	0.07	0
(Sep 30 2014)		(Jun 30 2025)

Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry	Quick Ratio	Jun 30 2026 MRQ Cash & cash equivalent	Jun 30 2026 MRQ Current Liabilities
Cannapharmarx Inc	0.00	$ 0.001 Millions	$ 12.120 Millions
Regen Biopharma Inc	0.00	$ 0.000 Millions	$ 7.891 Millions

Date modified: 2026-09-26T06:54:28+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.